FDA Fast Tracks YUTREPIA for Raynaud's in Systemic Sclerosis
LQDA has more than doubled off its 52-week low of $21.145.
Summary
The FDA granted Fast Track designation to YUTREPIA for Raynaud's phenomenon associated with systemic sclerosis (SSc-RP), a serious complication with no approved therapy. This designation provides more frequent FDA interactions, potential rolling review, and possible Priority Review or Accelerated Approval. Liquidia plans to start the RE-WARM Phase 2a study in October 2026, with primary completion targeted for February 2027. The addressable U.S. population is estimated at 30,000 patients with moderate to severe symptoms. This expands YUTREPIA's potential beyond its approved PAH and PH-ILD indications, though approval for SSc-RP is not guaranteed. The news follows strong Q2 results and ongoing insider selling, but this regulatory milestone is a fresh positive development.
At the time of this announcement, LQDA was trading at $72.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $21.15 to $93.61. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.